Life Molecular Imaging (LMI) has expanded their strategic partnership and licensing agreement with Jubilant Radiopharma to provide and distribute Neuraceq from Jubilant's single photon emission computed tomography (SPECT) and Positron Emision Tomography (PET) radiopharmaceutical manufacturing site located in Mobile, AL.

Neuraceq is an FDA-approved imaging agent for the detection of beta-amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.

Neuraceq is used in clinical routine and is also a powerful imaging biomarker for the appropriate characterization of subjects assessed for treatment eligibility with newly approved anti-amyloid drugs, or for enrollment in clinical trials to further support drug development in neurodegenerative diseases.

"Expanding Neuraceq manufacturing in Mobile in collaboration with Jubilant, further reinforces Life Molecular Imaging's commitment to meeting the increasing demand for amyloid detection to confirm eligibility for new therapies. We are excited to support the growing needs of the customers in the region, and to provide Neuraceq access for the benefit of physicians, patients, and our pharma partners," said Colleen Ruby, US Country and Chief Operating Officer, Americas and APAC. 

"More than 6.2 million Americans are currently living with Alzheimer's disease. A progressive brain disorder that impacts memory, thinking and language skills, and the ability to carry out the simplest tasks. The Jubilant Radiopharma Team is excited to bring Neuraceq to physicians and patients in the Mobile, AL area," said Renato Leite, President, Jubilant Radiopharmacies.

"The availability of Neuraceq offers new hope through the detection of beta-amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease," Leite added.